Johnson & Johnson (NYSE:JNJ) Stake Lessened by Csenge Advisory Group

Csenge Advisory Group lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 15.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,560 shares of the company's stock after selling 3,283 shares during the period. Csenge Advisory Group's holdings in Johnson & Johnson were worth $2,684,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. IFS Advisors LLC raised its position in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $35,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $3.27 during mid-day trading on Friday, hitting $162.95. 6,695,360 shares of the company's stock traded hands, compared to its average volume of 8,885,373. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market cap of $392.32 billion, a PE ratio of 24.49, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The firm's 50 day simple moving average is $148.61 and its 200 day simple moving average is $155.89. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period last year, the company earned $2.29 earnings per share. The company's quarterly revenue was up 5.3% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Tuesday, January 28th. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target for the company. Leerink Partners cut their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Finally, Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $170.67.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.